paraneoplastic syndromes

paraneoplastic syndromes

[-nē′əplas′tik]
Etymology: Gk, para + neos, new, plassein, to mold, syn, together, dromos, course
the indirect effects of a tumor that occur distant to the tumor or metastatic site. They may result from the production of active proteins, polypeptides, or inactive hormones by the tumor.

paraneoplastic syndrome

Oncology A co-morbid condition due to the indirect–remote or 'biologic' effects of malignancy, which may be the first sign of a neoplasm or its recurrence; PSs occur in > 15% of CAs, are caused by hormones, growth factors, biological response modifiers, and other as-yet unidentified factors, and may regress with treatment of the primary tumor. See Ectopic hormone.
Paraneoplastic syndromes
GI tract, eg anorexia, vomiting, protein-losing enteropathy, liver disease
Hematologic, eg leukemoid reaction, reactive eosinophilia, peripheral 'cytoses or 'cytopenias, hemolysis, DIC, thromboembolism, thrombophlebitis migrans
Hormonal effects
Metabolic disease, eg lactic acidosis, hypertrophic pulmonary osteoarthropathy, hyperamylasemia, hyperlipidemia
Neuromuscular, eg peripheral neuropathy, myopathy, CNS, spinal cord degeneration, inflammation
Renal, eg nephrotic syndrome, uric acid nephropathy
Skin, eg bullous mucocutaneous lesions, acquired ichthyosis, acanthosis nigricans, dermatomyositis
Others, eg callus formation, hypertension, and amyloidosis

paraneoplastic syndromes

(pă-ră-nēō-plăs′-tĭk)
Indirect effects of cancers, such as metabolic disturbances or hormonal excesses produced by chemicals released by tumor cells. Tumors such as small-cell carcinoma of the lung, hypernephroma, and neuroendocrine cancers are often responsible.

paraneoplastic syndromes

Syndromes caused by the secretion into the blood of the products of cancers, usually polypeptide hormones, which affect parts remote from the tumours. Thus, lung cancers can secrete ANTIDIURETIC HORMONE or ACTH and cause confusing effects.
References in periodicals archive ?
A possible role for alpha-transforming growth factor in cutaneous paraneoplastic syndromes.
The importance of understanding the pathophysiology and biology of many paraneoplastic syndromes associated with renal cell carcinoma (RCC) lies in the fact that these protean symptoms might be the initial presentation of some either primary or recurrent diseases.
2) Differential diagnosis of NL includes leptomeningeal lymphomatosis, nerve damage by herpes zoster or enlarged lymph nodes, chemotherapy or radiation plexopathy, and lymphoma associated vasculitis and paraneoplastic syndromes.
Paraneoplastic syndromes as lameness, secondary recurrent infections, septic arthritis, lymphadenopathy and laminitis, with prostration and depression complicate the evolution of case.
The pathogenesis of paraneoplastic syndromes is thought to be autoimmune, and they also do not respond well to steroid treatment.
It is more commonly associated with connective tissue disorders than paraneoplastic syndromes.
Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes.
There are a number of paraneoplastic syndromes associated with thymoma.
One theory is that DM and ADM represent paraneoplastic syndromes, where factors from a pre-existing tumour trigger an inflammatory or immune-mediated response leading to cutaneous manifestations, with or without the myopathy.
A combination of paraneoplastic syndromes as the presenting signs of recurrent breast cancer has not been well documented.
Melanoma growth factors acanthosis nigricans the sign of Leser-TrACopyrightlat and multiple acrochordons: a possible role for alpha-transforming growth factor in cutaneous paraneoplastic syndromes.
They usually do not metastasize and are not accompanied by other paraneoplastic syndromes that may endanger the patient's life.